. 2018 Dec 12;2:28. doi: 10.1038/s41698-018-0071-0

Table 2.

Additional patients and cohorts used for validation

Patient/cohort	Age	Gender	Diagnosis	Notesdysregulated miRNAs in serum exosomes
GBM1_relapse	46	M	GBM IV	Preoperative blood taken after recurrence of GBM1 (8-month relapse)
GBM12_prior	45	F	GBM IV	Preoperative blood taken before removal of earlier GBM lesion (GBM12; 4.6 months prior)
GBM13	33	M	GBM IV	Glioblastoma, IDH^MUT, WHO (2016) grade IV
GBM14	56	M	High-grade glioma	No surgery/tissue pathology performed, diagnosis based on repeat MRIs. Overall survival of 8.1 months
GI_C	24	F	Ganglioglioma grade I	GFAP⁺ in glial component/NeuN⁺ in neuronal component, IDH1^WT, ATRX⁺, BRAF(V600E)⁺⁺⁺
HC (n = 9)	36.2 ± 10.3	5 F, 4 M	Healthy controls	—
MS_C (n = 9)	35.3 ± 10.4	5 M, 4 F	Relapse-remitting multiple sclerosis	All patients had active lesions, were untreated (n = 5) or receiving different immunomodulatory therapies (n = 4)

For more detailed demographic, clinical, and histopathologic information, please refer to Supplementary Tables 2A-B. The mean age with standard deviation is provided for each cohort

F female, GBM glioblastoma, GII–III glioma grade II–III, GI_C ganglioglioma grade I control case, HC healthy controls, M male, MS_C multiple sclerosis control cohort